1,137
Views
43
CrossRef citations to date
0
Altmetric
Pharmacotherapy

A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Omalizumab on Asthma Control in Patients with Persistent Allergic Asthma

, M.D., , Ph.D., , Ph.D. & , Ph.D.
Pages 144-152 | Published online: 25 Jan 2012

References

  • American Lung Association. Trends in asthma morbidity and mortality. Updated July 2011. Available at: http://www.lungusa.org/finding-cures/our-research/trend-reports/asthma-trend-report.pdf. Accessed November 15, 2011.
  • National Heart Lung and Blood Institute. Expert Panel Report 3: guidelines for the diagnosis and management of asthma summary report 2007. NIH Publication No. 08-5846. Published October 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthsumm.htm. Accessed November 15, 2011.
  • Peters SP, Jones CA, Haselkorn T, . Real-world evaluation of asthma control and treatment (REACT): findings from a national web-based survey. J Allergy Clin Immunol 2007; 119:1454–1461.
  • Chapman KR, Boulet LP, Rea RM, . Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008; 31:320–325.
  • Busse W, Corren J, Lanier BQ, . Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184–190.
  • Soler M, Matz J, Townley R, . The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254–261.
  • Holgate ST, Chuchalin AG, Hebert J, . Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632–638.
  • Hanania NA, Alpan O, Hamilos DL, . Omalizumab in severe allergic asthma inadequately controlled on standard therapy: a randomized trial. Ann Intern Med. In press.
  • Pauwels RA. Similarities and differences in asthma and chronic obstructive pulmonary disease exacerbations. Proc Am Thorac Soc 2004; 1:73–76.
  • Pedersen S, Dubus JC, Crompton GK. The ADMIT series—issues in inhalation therapy. 5) Inhaler selection in children with asthma. Prim Care Respir J 2010; 19:209–216.
  • Schatz M, Sorkness CA, Li JT, . Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol 2006; 117:549–556.
  • Nathan RA, Sorkness CA, Kosinski M, . Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59–65.
  • Schatz M, Mosen DM, Kosinski M, . Validity of the Asthma Control Test completed at home. Am J Manag Care 2007; 13:661–667.
  • Schatz M, Kosinski M, Yarlas AS, . The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol 2009; 124:719–723.
  • Lloyd A, Turk F, Leighton T, . Psychometric evaluation of Global Evaluation of Treatment Effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. J Med Econ 2007; 10:285–296.
  • Andréasson E, Svensson K, Berggren F Validity of the work productivity and activity impairment questionnaire for patients with asthma (WPAI-asthma): results from a web-based study. Poster presented at 8th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; May 18–21, 2003; Arlington, VA.
  • Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993; 4:353–365.
  • Busse WW, Morgan WJ, Gergen PJ, . Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364:1005–1015.
  • Stokes ME, Davis CS, Koch GG. Categorical Data Analysis using the SAS System. 2nd ed. Cary, NC: SAS Institute, 2000.
  • Chen M, Kianifard F. A nonparametric procedure associated with a clinically meaningful efficacy measure. Biostatistics 2000; 1:293–298.
  • Kianifard F, Gallo PP. Poisson regression analysis in clinical research. J Biopharm Stat 1995; 5:115–129.
  • National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute; 2007. NIH Publication No. 07–4051.
  • Piacentini GL, Peroni DG, Bodini A, . Childhood Asthma Control Test and airway inflammation evaluation in asthmatic children. Allergy 2009; 64:1753–1757.
  • Reddel HK, Taylor DR, Bateman ED, Boulet, LP, Boushey, HA, Busse, WW, Casale, TB, Chanez, P, Enright, PL, Gibson, PG, de Jongste, JC, Kerstjens, HA, Lazarus, SC, Levy, ML, O'Byrne, PM, Partridge, MR, Pavord, ID, Sears, MR, Sterk, PJ, Stoloff, SW, Sullivan, SD, Szefler, SJ, Thomas, MD, Wenzel, SE. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180:59–99.
  • Harris JM, Wong DA, Kapp AV. Development of the Asthma Control Composite outcome measure to predict omalizumab response. Ann Allergy Asthma Immunol 2011; 107:273–280.
  • Schatz M, Zeiger RS, Drane A, . Reliability and predictive validity of the Asthma Control Test administered by telephone calls using speech recognition technology. J Allergy Clin Immunol 2007; 119:336–343.
  • Toren K, Brisman J, Jarvholm B. Asthma and asthma-like symptoms in adults assessed by questionnaires. A literature review. Chest 1993; 104:600–608.
  • Macy E, Schatz M, Gibbons C, . The prevalence of reversible airflow obstruction and/or methacholine hyperreactivity in random adult asthma patients identified by administrative data. J Asthma 2005; 42:213–220.
  • Crim C. Clinical practice guidelines vs actual clinical practice: the asthma paradigm. Chest 2000; 118:62S–64S.
  • O’Dowd LC, Fife D, Tenhave T, . Attitudes of physicians toward objective measures of airway function in asthma. Am J Med 2003; 114:391–396.
  • Doerschug KC, Peterson MW, Dayton CS, . Asthma guidelines: an assessment of physician understanding and practice. Am J Respir Crit Care Med 1999; 159:1735–1741.
  • Kikuchi Y, Okabe S, Tamura G, . Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma. N Engl J Med 1994; 330:1329–1334.
  • Bijl-Hofland ID, Cloosterman SG, van Schayck CP, . Perception of respiratory sensation assessed by means of histamine challenge and threshold loading tests. Chest 2000; 117:954–959.
  • Bousquet J, Wenzel S, Holgate S, . Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125:1378–1386.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.